Molecular Partners AGNASDAQ:MOLN
- LAST PRICE5.4200
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots5.3000/ 6
- Ask / Lots5.4500/ 6
- Open / Previous Close--- / 5.4200
- Day Range---
- 52 Week Range
- Volume215
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MOLN |
|---|---|---|
| 09:37 ET | 655 | 5.48 |
| 09:48 ET | 200 | 5.47 |
| 09:51 ET | 1284 | 5.47 |
| 10:13 ET | 4992 | 5.2 |
| 10:22 ET | 100 | 5.3 |
| 11:21 ET | 700 | 5.41 |
| 11:36 ET | 200 | 5.34 |
| 03:42 ET | 2066 | 5.42 |
Nov 7, 2024
Nov 5, 2024
Molecular Partners Announces Upcoming Poster Presentations at the 65th ASH Annual Meeting and Exposition, from 4:00PM ET on Tuesday Nov 05, 2024 by Dow Jones
4:00PM ET on Tuesday Nov 05, 2024 by Dow Jones
Oct 31, 2024
Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going, from 4:00PM ET on Thursday Oct 31, 2024 by Dow Jones
4:00PM ET on Thursday Oct 31, 2024 by Dow JonesPress Release: Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going, from 4:00PM ET on Thursday Oct 31, 2024 by Dow Jones
4:00PM ET on Thursday Oct 31, 2024 by Dow Jones
Oct 25, 2024
Molecular Partners Announces Pricing of $20 Million Underwritten Offering, from 1:00AM ET on Friday Oct 25, 2024 by Dow Jones
1:00AM ET on Friday Oct 25, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Molecular Partners AG | 219.9M | -2.7x | --- |
Ocugen Inc | 262.5M | -4.9x | --- |
Abeona Therapeutics Inc | 250.8M | -2.5x | --- |
aTyr Pharma Inc | 250.1M | -3.2x | --- |
Eledon Pharmaceuticals Inc | 243.1M | -10.5x | --- |
ATAI Life Sciences NV | 255.1M | -1.9x | --- |
Company Information
Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
Contact Information
- Headquarters
- Wagistrasse 14SCHLIEREN, Switzerland 8952
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Independent Chairman of the Board
- William Burns
- Chief Executive Officer, Executive Director, Member of the Management Board
- Patrick Amstutz
- Chief Operating Officer, Member of the Management Board
- Alexander Zurcher
- Executive Vice President - People and Community, Member of the Management Board
- Renate Gloggner
- Executive Vice President - Projects, Member of the Management Board
- Michael Stumpp
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $219.9M |
|---|---|
Revenue (TTM) | $8.9M |
Shares Outstanding | 40.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.98 |
EPS | $-1.97 |
Book Value | $6.06 |
P/E Ratio | -2.7x |
Price/Sales (TTM) | 24.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -788.23% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
